These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 16022909

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis.
    Dong QG, Sclabas GM, Fujioka S, Schmidt C, Peng B, Wu T, Tsao MS, Evans DB, Abbruzzese JL, McDonnell TJ, Chiao PJ.
    Oncogene; 2002 Sep 19; 21(42):6510-9. PubMed ID: 12226754
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
    Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, Hahn S, Schreiber S, Wilhelm S, Herrmann M, Jäck HM, Voll RE.
    Cancer Res; 2007 Feb 15; 67(4):1783-92. PubMed ID: 17308121
    [Abstract] [Full Text] [Related]

  • 7. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
    Denlinger CE, Rundall BK, Jones DR.
    J Thorac Cardiovasc Surg; 2004 Nov 15; 128(5):740-8. PubMed ID: 15514602
    [Abstract] [Full Text] [Related]

  • 8. JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways.
    Lauricella M, Emanuele S, D'Anneo A, Calvaruso G, Vassallo B, Carlisi D, Portanova P, Vento R, Tesoriere G.
    Apoptosis; 2006 Apr 15; 11(4):607-25. PubMed ID: 16528474
    [Abstract] [Full Text] [Related]

  • 9. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL.
    Cancer Res; 2008 Aug 15; 68(16):6698-707. PubMed ID: 18701494
    [Abstract] [Full Text] [Related]

  • 10. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).
    Yin D, Zhou H, Kumagai T, Liu G, Ong JM, Black KL, Koeffler HP.
    Oncogene; 2005 Jan 13; 24(3):344-54. PubMed ID: 15531918
    [Abstract] [Full Text] [Related]

  • 11. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
    von Metzler I, Heider U, Mieth M, Lamottke B, Kaiser M, Jakob C, Sezer O.
    Exp Cell Res; 2009 Aug 15; 315(14):2471-8. PubMed ID: 19410573
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins.
    Wolter KG, Verhaegen M, Fernández Y, Nikolovska-Coleska Z, Riblett M, de la Vega CM, Wang S, Soengas MS.
    Cell Death Differ; 2007 Sep 15; 14(9):1605-16. PubMed ID: 17541428
    [Abstract] [Full Text] [Related]

  • 14. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, Sun SY.
    Cancer Res; 2007 May 15; 67(10):4981-8. PubMed ID: 17510429
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
    Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, Bennett F, Pollock PM, Trent JM, Hendrix MJ, Rizzo P, Miele L, Nickoloff BJ.
    Cancer Res; 2005 Jul 15; 65(14):6282-93. PubMed ID: 16024630
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rötzer S, Rademacher J, Jakob C, Fleissner C, Kuckelkorn U, Kloetzel PM, Sezer O.
    Eur J Haematol; 2008 Feb 15; 80(2):133-42. PubMed ID: 18005386
    [Abstract] [Full Text] [Related]

  • 19. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib.
    Emanuele S, Lauricella M, Carlisi D, Vassallo B, D'Anneo A, Di Fazio P, Vento R, Tesoriere G.
    Apoptosis; 2007 Jul 15; 12(7):1327-38. PubMed ID: 17351739
    [Abstract] [Full Text] [Related]

  • 20. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
    Nakata W, Hayakawa Y, Nakagawa H, Sakamoto K, Kinoshita H, Takahashi R, Hirata Y, Maeda S, Koike K.
    Int J Oncol; 2011 Dec 15; 39(6):1529-36. PubMed ID: 21785822
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.